Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Total Liabilities: 2017-2025

Historic Total Liabilities for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $96.3 million.

  • Cidara Therapeutics' Total Liabilities rose 106.13% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.3 million, marking a year-over-year increase of 106.13%. This contributed to the annual value of $51.5 million for FY2024, which is 31.57% down from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Total Liabilities is $96.3 million, which was up 190.35% from $33.2 million recorded in Q2 2025.
  • Cidara Therapeutics' Total Liabilities' 5-year high stood at $96.3 million during Q3 2025, with a 5-year trough of $33.2 million in Q2 2025.
  • In the last 3 years, Cidara Therapeutics' Total Liabilities had a median value of $65.9 million in 2023 and averaged $60.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 35.65% in 2024, then soared by 106.13% in 2025.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Total Liabilities stood at $53.8 million in 2021, then increased by 15.21% to $61.9 million in 2022, then increased by 21.50% to $75.2 million in 2023, then tumbled by 31.57% to $51.5 million in 2024, then spiked by 106.13% to $96.3 million in 2025.
  • Its Total Liabilities stands at $96.3 million for Q3 2025, versus $33.2 million for Q2 2025 and $50.0 million for Q1 2025.